CymaBay Therapeutics Inc (NASDAQ:CBAY)
| 15.18 BATS BZX Real-Time Price As of 2:00pm ET |  -0.39 / -2.50%Today’s Change | 3.16 Today|||52-Week Range 18.20 | +142.11% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Quarter Trend | |||||
|---|---|---|---|---|---|---|
| Quarter 3 2018 | Quarter 4 2018 | Quarter 1 2019 | Quarter 2 2019 | |||
| Assets | Cash | 41.8M | 49.0M | 125.6M | 28.1M | |
| Short Term Investment Cash | -2.9M | 7.2M | 76.6M | -97.5M | ||
| Cash & Short Term Investments | 198.1M | 178.7M | 264.8M | 241.2M | ||
| Receivables | Receivables | 217.0K | 0.00 | 481.0K | 725.0K | |
| Inventories | Inventories | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Current Assets | Prepaid Expenses | 1.8M | 2.6M | 4.8M | 7.9M | |
| Other Current Assets | 2.1M | 304.0K | 0.00 | 0.00 | ||
| Current Assets | 202.3M | 181.6M | 270.1M | 249.8M | ||
| Total Assets | Property, Plant and Equipment - Gross | -- | 3.0M | -- | -- | |
| Depreciation | -- | -130.0K | -- | -- | ||
| Other Assets | 1.4M | 2.3M | 1.1M | 730.0K | ||
| Total Assets | 203.7M | 186.7M | 274.2M | 253.4M | ||
| Liabilities | Accounts Payable | 1.6M | 2.0M | 2.4M | 2.9M | |
| Short Term Debt | 0.00 | 0.00 | 357.0K | 373.0K | ||
| Accrued Expenses | 10.2M | 9.7M | 10.5M | 10.2M | ||
| Other Current Liabilities | 10.2M | 9.7M | 10.5M | 10.2M | ||
| Other Liabilities | 13.6M | 14.4M | 14.5M | 15.4M | ||
| Total Liabilities | Long Term Debt | 0.00 | 0.00 | 2.1M | 2.0M | |
| Other Liabilities | 1.9M | 1.9M | 0.00 | 0.00 | ||
| Total Liabilities | 15.6M | 16.3M | 16.5M | 17.4M | ||
| Equity | Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Preferred Stock | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Equity | 188.1M | 170.4M | 257.6M | 236.1M | ||
| Total Shareholder Equity | 188.1M | 170.4M | 257.6M | 236.1M | ||
| Share Information | Common Shares Outstanding | 59.4M | 59.5M | 68.7M | 68.7M | |
| Addtl. Info. | No data currently available for this section. | |||||
